GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vivos Therapeutics Inc (NAS:VVOS) » Definitions » Short-Term Debt & Capital Lease Obligation

Vivos Therapeutics (Vivos Therapeutics) Short-Term Debt & Capital Lease Obligation : $0.48 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vivos Therapeutics Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Vivos Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.48 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Vivos Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.40 Mil.


Vivos Therapeutics Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Vivos Therapeutics's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivos Therapeutics Short-Term Debt & Capital Lease Obligation Chart

Vivos Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt & Capital Lease Obligation
Get a 7-Day Free Trial 3.71 0.87 1.33 0.42 0.47

Vivos Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Short-Term Debt & Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.45 0.46 0.47 0.48

Vivos Therapeutics Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


Vivos Therapeutics Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Vivos Therapeutics's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivos Therapeutics (Vivos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
7921 Southpark Plaza, Suite 210, Littleton, CO, USA, 80120
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System.
Executives
Ronald Kirk Huntsman director, 10 percent owner, officer: Chairman & CEO 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Bradford K. Amman officer: Chief Financial Officer 6400 S. FIDDLER'S GREEN CIRCLE, SUITE 1970, GREENWOOD VILLAGE X1 80111
Leonard J Sokolow director REGATTA OFFICE PARK, WINDWARD THREE, 4TH FLOOR, WEST BAY ROAD, P.O. BOX 1114, GRAND CAYMAN E9 E9 KY11102
Matthew Thompson director 2 MUSICK, IRVINE CA 92618
Anja B Krammer director C/O BIOPHARMX CORPORATION, 1505 ADAMS DRIVE, SUITE D, MENLO PARK CA 94025
Gurdev Dave Singh director, 10 percent owner, officer: Chief Medical Officer 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Mark F. Lindsay director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129
Ralph Elias Green director 9137 RIDGELINE BOULEVARD, SUITE 135, HIGHLANDS RANCH CO 80129

Vivos Therapeutics (Vivos Therapeutics) Headlines